IV Ketamine + Propofol-ECT for Treatment-Resistant Depression: Pilot fMRI Study (Zhang 2020, Tianjin Anding Hospital)
This unregistered trial (n=28) was a pilot study of intravenous ketamine combined with propofol-electroconvulsive therapy for treatment-resistant depression in adults, finding that the combination improved antidepressant effects for approximately seven days.
Continue exploring
Continue exploring this trial
Move from the registry record to the most relevant public research context.
Detailed Description
This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.
The study investigated the efficacy of combining intravenous ketamine with propofol-electroconvulsive therapy (ECT) in patients with depression that had proven resistant to standard ECT. The intervention involved six doses of ketamine and six sessions of bilateral ECT administered over a two-week period.
Results indicated that the addition of ketamine improved antidepressant outcomes compared to ECT alone. Neuroimaging via resting-state fMRI showed increased global functional connectivity density in the left temporal and subgenual anterior cingulate cortex, alongside decreased functional connectivity strength within the default mode network. While functional brain alterations persisted for ten days, the clinical antidepressant effect was observed to last for seven days.
Study Arms & Interventions
Ketamine 35 mg/70 kg + propofol-ECT 70 mg/70 kg
experimentalPatients received intravenous ketamine and propofol-electroconvulsive therapy (ECT) alternately.
Interventions
- Ketamine0.5 mg/kgvia IV• six times within 14 days• 6 doses total
Injected at 10:00 pm the day before propofol-ECT
- Placebo1 mg/kgvia IV• six times within 14 days• 6 doses total
Used as anaesthetic during ECT; dose range 1-2 mg/kg
- Placebovia null• six times within 14 days• 6 doses total
Bilateral ECT; stimulus intensity adjusted by energy percentage
Propofol-ECT 70 mg/70 kg
active comparatorPatients received propofol-electroconvulsive therapy (ECT) only.
Interventions
- Placebo1 mg/kgvia IV• six times within 14 days• 6 doses total
Used as anaesthetic during ECT; dose range 1-2 mg/kg
- Placebovia null• six times within 14 days• 6 doses total
Bilateral ECT
Study Protocol, Arms & Participants
Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.
Study Details
- StatusCompleted
- PhasePhase II
- Typeinterventional
- DesignNon-randomized
- Target Enrollment28 participants
- TimelineStart: 2014-12-01End: 2018-12-01
- Compounds
- Topic
Locations
Related Publications
Recent activity
- PaperKetamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depressi…
- CompletedIV Ketamine + Propofol-ECT for Treatment-Resistant Depression: Pilot fMRI Study (Zhang 2020, Tianjin Anding Hospital) (ketamine)
- StartedIV Ketamine + Propofol-ECT for Treatment-Resistant Depression: Pilot fMRI Study (Zhang 2020, Tianjin Anding Hospital) (ketamine)
Your Personal Research Library
Go Pro to save trials, add notes, rate research, and organize custom shelves.